Managing the "known unknowns": theranostic cancer nanomedicine and informed consent

Area of Science:

• Nanomedicine
• Bioethics
• Clinical Research

Background:

• Theranostics present significant clinical and economic advantages, driving research and development.
• Potential downsides, particularly concerning informed consent, require careful examination.
• Nanoparticle applications in medicine raise novel ethical and regulatory questions.

Purpose of the Study:

• To analyze how theranostics may impact current informed consent processes.
• To explore challenges in disclosing diagnostic and treatment information for human subjects in theranostics.
• To address the implications of data gaps regarding long-term nanoparticle effects.

Main Methods:

• Literature review and ethical analysis of theranostics and informed consent principles.
• Examination of existing frameworks for risk disclosure and management in nanomedicine.
• Discussion of the "upstream" approach for stakeholder communication and transparency.

Main Results:

• Lack of data on long-term health and environmental risks of nanoparticles complicates risk-benefit assessments for informed consent.
• Current informed consent models may be insufficient for complex theranostic interventions.
• An "upstream" approach emphasizing early and continuous communication is proposed.

Conclusions:

• Theranostics necessitate a re-evaluation of informed consent procedures, particularly regarding nanoparticle safety data.
• Effective risk management in nanomedicine requires transparency and proactive engagement with all stakeholders.
• Adopting an "upstream" approach can foster informed decision-making, ensuring both patient safety and scientific advancement.